Regulus Therapeutics Inc (RGLS) - Total Liabilities

Latest as of March 2025: $5.80 Million USD

Based on the latest financial reports, Regulus Therapeutics Inc (RGLS) has total liabilities worth $5.80 Million USD as of March 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore RGLS operating cash flow to assess how effectively this company generates cash.

Regulus Therapeutics Inc - Total Liabilities Trend (2010–2024)

This chart illustrates how Regulus Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. Check RGLS asset resilience ratio to evaluate the company's liquid asset resilience ratio.

Regulus Therapeutics Inc Competitors by Total Liabilities

The table below lists competitors of Regulus Therapeutics Inc ranked by their total liabilities.

Company	Country	Total Liabilities
Il Dong Pharmaceutical Co Ltd KO:249420	Korea	₩347.04 Billion
Duzhe Publishing & Media Corp SHG:603999	China	CN¥514.03 Million
Mills Estruturas e Serviços de Engenharia S.A SA:MILS3	Brazil	R$2.80 Billion
SNT Motiv Co Ltd KO:064960	Korea	₩259.97 Billion
uPI Semiconductor Corp TW:6719	Taiwan	NT$2.87 Billion
Pilani Investment and Industries Corporation Limited NSE:PILANIINVS	India	Rs37.87 Billion
Shanghai Phoenix Enterprise Group Co Ltd A SHG:600679	China	CN¥1.44 Billion
Sijin Intelligent Forming Machinery SHE:003025	China	CN¥298.46 Million

Liability Composition Analysis (2010–2024)

This chart breaks down Regulus Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see RGLS market cap.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	16.31	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	0.08	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.08	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Regulus Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Regulus Therapeutics Inc (2010–2024)

The table below shows the annual total liabilities of Regulus Therapeutics Inc from 2010 to 2024.

Year	Total Liabilities	Change
2024-12-31	$7.77 Million	-18.72%
2023-12-31	$9.56 Million	-28.77%
2022-12-31	$13.43 Million	-0.53%
2021-12-31	$13.50 Million	+16.57%
2020-12-31	$11.58 Million	-47.53%
2019-12-31	$22.07 Million	-34.68%
2018-12-31	$33.78 Million	-20.69%
2017-12-31	$42.59 Million	-4.47%
2016-12-31	$44.59 Million	+162.19%
2015-12-31	$17.00 Million	-56.91%
2014-12-31	$39.47 Million	+33.30%
2013-12-31	$29.61 Million	-28.53%
2012-12-31	$41.42 Million	-50.90%
2011-12-31	$84.38 Million	+63.18%
2010-12-31	$51.71 Million	--

About Regulus Therapeutics Inc

NASDAQ:RGLS USA Biotechnology

Market Cap

$564.95 Million

Market Cap Rank

#11908 Global

#2828 in USA

Share Price

$8.16

Change (1 day)

+0.25%

52-Week Range

$7.83 - $8.30

All Time High

$1269.60